OSE Immunotherapeutics SA and France's second largest drug maker Servier SA have agreed to develop and commercialize the biotech's IL-7 antagonist Effi-7 in ulcerative colitis in a deal that could be worth up to €272m to the newly formed group.
The pact, announced Dec. 28, will see privately owned Servier pay OSE Immunotherapeutics €10.25m ($10.71m) for an option to license...